Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option

Abstract

The recent results of Protocol T have illustrated the efficacy of aflibercept in the treatment of diabetic macular edema. It also demonstrated that in patients with poor vision (o6/12), aflibercept offers anatomical and visual advantages over ranibizumab and bevacizumab in the first 12 months of treament. At 2 years, the difference between the three drugs decreased with patients with a better baseline VA (69-78) showing a statistically insignificant advantage for ranibizumab compared with aflibercept. These results were achieved using a pro-re nata (PRN) protocol, which was not previously studied in large phase 3 trials, VIVID and VISTA, that chose to compare the 2.0 mg dose in a monthly and bimonthly regimen. In this review article, we analyzed earlier studies such as DAVINCI and VIVID and VISTA to determine which treatment strategy offers the best results; monthly, bimonthly, or PRN. We also studied the different doses for aflibercept used in DAVINCI to determine which is more effective the 0.5 mg dose or the 2.0 mg dose. In addition, we analyzed the recent data from protocol T with regards to visual and anatomic outcomes to try to determine whether these results concur with previous studies. Finally, we discuss the role of aflibercept as a potential alternative to any diabetic macular edema regimen regardless what the primary drug used is.

Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings

“…Some advocate early switching as prolonged DMO can lead to permanent structural damage to the neural retina, hindering visual gain, as seen in the delayed anti-VEGF treatment arms of the RISE/RIDE and VISTA/VIVID trials [28,29]. In contrast, others advocate delaying the decision to switch anti-VEGF agents due to the possibility of late response [30].…”

Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema

“…DME affects 14-25% of patients who have had diabetes for 10 years or more [7].Anti-vascular endothelial growth factor (VEGF) therapy is the most commonly used treatment approach in the management of DME [8,9]. The advantage of intravitreal administration of an anti-VEGF drug in patients with DME has been identified and effectively applied in large, multicenter, randomized clinical trials [8,10,11]. However, Brown and colleagues [12] estimated that between 31.6% and 65.6% of patients with DME respond suboptimally to anti-VEGFs.…”